MPTP: current concepts and controversiesLANGSTON, J. W; IRWIN, I.Clinical neuropharmacology. 1986, Vol 9, Num 6, pp 485-507, issn 0362-5664Article

Intellectual changes in patients with MPTP-induced parkinsonismSTERN, Y; LANGSTON, J. W.Neurology. 1985, Vol 35, Num 10, pp 1506-1509, issn 0028-3878Article

MPTP and aging : studies in the C57BL/6 mouseIRWIN, I; DELANNEY, L. E; LANGSTON, J. W et al.Advances in neurology. 1993, Vol 60, pp 197-206, issn 0091-3952Article

Unfavorable outcome of adrenal medullary transplant for Parkinson's diseaseFORNO, L. S; LANGSTON, J. W.Acta neuropathologica. 1991, Vol 81, Num 6, pp 691-694, issn 0001-6322Article

Selegiline and Parkinson's disease protective and symptomatic condiserationsGOLBE, L. I; LANGSTON, J. W; SHOULSON, I et al.Drugs (Basel). 1990, Vol 39, Num 5, pp 646-651, issn 0012-6667Article

The next frontier in Parkinson's disease : presymptomatic detectionLANGSTON, J. W; KOLLER, W. C.Neurology. 1991, Vol 41, Num 5, pp 5-7, issn 0028-3878, 3 p., SUP2Conference Paper

Symposium on the etiology, pathogenesis, and prevention of Parkinson's diseaseSHOULSON, I; FAHN, S; LANGSTON, J. W et al.Archives of neurology (Chicago). 1988, Vol 45, Num 7, pp 807-811, issn 0003-9942Article

Curved reconstruction along the anterior optic pathwayGRONEMEYER, S. A; LANGSTON, J. W; ABRAHAM, J et al.American journal of neuroradiology. 1998, Vol 19, Num 2, pp 338-340, issn 0195-6108Article

Protective and preventive therapeutic strategies : monoamine oxidase inhibitorsTETRUD, J. W; LANGSTON, J. W.Neurologic clinics. 1992, Vol 10, Num 2, pp 541-552, issn 0733-8619Article

MPTP-induced parkinsonism as a model for Parkinson's diseaseTETRUD, J. W; LANGSTON, J. W.Acta neurologica Scandinavica. Supplementum. 1989, Vol 80, Num 126, pp 35-40, issn 0065-1427, 6 p.Article

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brainPIU CHAN; DI MONTE, D. A; LANGSTON, J. W et al.Brain research. 1994, Vol 647, Num 2, pp 249-254, issn 0006-8993Article

Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytesWU, E. Y; LANGSTON, J. W; DI MONTE, D. A et al.The Journal of pharmacology and experimental therapeutics. 1992, Vol 262, Num 1, pp 225-230, issn 0022-3565Article

Saccade responses to dopamine in human MPTP-induced parkinsonismHOTSON, J. R; LANGSTON, E. B; LANGSTON, J. W et al.Annals of neurology. 1986, Vol 20, Num 4, pp 456-463, issn 0364-5134Article

Failure to find the α-synuclein gene missense mutation (G²⁰⁹A) in 100 patients with younger onset Parkinson's diseasePIU CHAN; TANNER, C. M; XIN JIANG et al.Neurology. 1998, Vol 50, Num 2, pp 513-514, issn 0028-3878Article

Selegiline and mortality in Parkinson's diseaseOLANOW, C. W; FAHN, S; LANGSTON, J. W et al.Annals of neurology. 1996, Vol 40, Num 6, pp 841-845, issn 0364-5134Article

Value of subtraction images in the detection of hemorrhagic brain lesions on contrast-enhanced MR imagesHANNA, S. L; LANGSTON, J. W; GRONEMEYER, S. A et al.American journal of neuroradiology. 1991, Vol 12, Num 4, pp 681-685, issn 0195-6108Article

Gd-DTPA enhancement of CSF in meningeal carcinomatosisPUI, M. H. W; LANGSTON, J. W; ARAI, Y et al.Journal of computer assisted tomography. 1993, Vol 17, Num 6, pp 940-944, issn 0363-8715Article

MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP⁺ elimination in the mouse striatumPIU CHAN; LANGSTON, J. W; DI MONTE, D. A et al.The Journal of pharmacology and experimental therapeutics. 1993, Vol 267, Num 3, pp 1515-1520, issn 0022-3565Article

Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriersMARRAS, C; SCHUELE, B; CHUANG, R. S.-I et al.Neurology. 2011, Vol 77, Num 4, pp 325-333, issn 0028-3878, 9 p.Article

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson diseaseOLANOW, C. W; KIEBURTZ, K; STERN, M et al.Archives of neurology (Chicago). 2004, Vol 61, Num 10, pp 1563-1568, issn 0003-9942, 6 p.Article

Parkin-proven disease: Common founders but divergent phenotypesLINCOLN, S; WILEY, J; MARDER, K et al.Neurology. 2003, Vol 60, Num 10, pp 1605-1610, issn 0028-3878, 6 p.Article

Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonismSNOW, B. J; VINGERHOETS, F. J. G; LANGSTON, J. W et al.Journal of neurology, neurosurgery and psychiatry. 2000, Vol 68, Num 3, pp 313-316, issn 0022-3050Article

Retinoblastoma : Sonographic findings with pathologic correlation in pediatric patientsKASTE, S. C; JENKINS, J. J; PRATT, C. B et al.American journal of roentgenology (1976). 2000, Vol 175, Num 2, pp 495-501, issn 0361-803XConference Paper

Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain : Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and levodopa treatmentHE, L; DI MONTE, D. A; LANGSTON, J. W et al.Neuroscience. 2000, Vol 99, Num 4, pp 697-704, issn 0306-4522Article

Differential alterations in nicotinic receptor α6 and β3 subunit messenger rnas in monkey substantia nigra after nigrostriatal degenerationQUIK, M; POLONSKAYA, Y; GILLESPIE, A et al.Neuroscience. 2000, Vol 100, Num 1, pp 63-72, issn 0306-4522Article